Its discovery traces back over 150 years to research on glucosuria ( By blocking sodium-glucose cotransporter 2 in the S1 and S2 segments of the proximal tubule, SGLT2i significantly reduce glucose reabsorption, promoting urinary glucose excretion
Some gastrointestinal claims, including gastroparesis, may require objective diagnostic testing or a documented diagnosis
Youll still start with 0.25 mg a week for the first month and gradually increase to the maintenance dose of 2.4 mg a week
About the Author: Julia Lloyd, MPH, RD, LDN, CDCES, is a registered dietitian and diabetes educator specializing in GLP-1 counseling
Both medicines affect GLP-1 pathways and share a dominant side-effect profile: nausea, vomiting, diarrhoea, constipation and abdominal discomfort, especially during dose escalation
thus, they were hypothesised as a treatment for BED [19, 20]